Nektar Therapeutics (NKTR) Accumulated Expenses (2010 - 2026)

Nektar Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• In Q1 2026, Accumulated Expenses changed 0.36% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $5.0 million (changed 0.36% YoY), while the FY2025 annual figure was $2.9 million, down 90.19% from the prior year.
• Accumulated Expenses was $5.0 million for Q1 2026 at Nektar Therapeutics, up from $2.9 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $37.4 million in Q1 2023 to a low of $2.9 million in Q4 2025.
• Historically, Accumulated Expenses has averaged $17.7 million across 5 years, with a median of $11.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 439.74% in 2024, then slumped 90.19% in 2025.
• A 5-year view of Accumulated Expenses shows it stood at $9.6 million in 2022, then slumped by 42.05% to $5.6 million in 2023, then surged by 439.74% to $30.0 million in 2024, then plunged by 90.19% to $2.9 million in 2025, then jumped by 70.34% to $5.0 million in 2026.
• The last three Accumulated Expenses figures came in at $5.0 million (Q1 2026), $2.9 million (Q4 2025), and $8.6 million (Q3 2025), per Business Quant data.